Lincoln Pharmaceuticals Intrinsic Value

Lincoln Pharmaceuticals (LINCOLN) median intrinsic value is ₹616.76 from 9 valuation models (range ₹255–₹878), vs current price ₹758.15 — -18.6% downside (Trading Above Median Value), margin of safety -22.9%. Browse LINCOLN income statement for revenue, profit, balance sheet and cash flow data.

Current Stock Price
₹758.15
Primary Intrinsic Value
₹878.24
Market Cap
₹1516 Cr
-18.6% Downside
Median Value
₹616.76
Value Range
₹255 - ₹878
Assessment
Trading Above Median Value
Safety Margin
-22.9%

LINCOLN Valuation Methods Summary — DCF, Graham Number & P/E

Lincoln Pharmaceuticals intrinsic value across 9 models vs current price ₹758.15 — upside/downside and value range per method. Also explore LINCOLN price trends to track price trends across different timeframes.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹878.24 ₹702.59 - ₹1053.89 +15.8% EPS: ₹39.92, Sector P/E: 22x
Book Value Method asset ₹672.00 ₹604.80 - ₹739.20 -11.4% Book Value/Share: ₹336.00, P/B: 2.0x
Revenue Multiple Method revenue ₹684.00 ₹615.60 - ₹752.40 -9.8% Revenue/Share: ₹342.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹660.00 ₹594.00 - ₹726.00 -12.9% EBITDA: ₹132.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹480.22 ₹384.18 - ₹576.26 -36.7% CF Growth: 7.7%, Discount: 15%
PEG Ratio Method growth ₹255.49 ₹229.94 - ₹281.04 -66.3% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹616.76 ₹555.08 - ₹678.44 -18.6% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹480.00 ₹432.00 - ₹528.00 -36.7% ROE: 11.9%, P/E Multiple: 12x
Graham Defensive Method conservative ₹549.36 ₹494.42 - ₹604.30 -27.5% EPS: ₹39.92, BVPS: ₹336.00
Method Types: Earnings Asset DCF Growth Dividend Conservative

LINCOLN Intrinsic Value vs Market Price — All Valuation Models

Lincoln Pharmaceuticals fair value range ₹255–₹878 vs current market price ₹758.15 across 9 valuation models. For current market price and key ratios, visit LINCOLN screener.

LINCOLN Intrinsic Value Analysis — Undervalued or Overvalued?

Lincoln Pharmaceuticals median intrinsic value ₹616.76, current price ₹758.15 — Trading Above Median Value by 18.6%, margin of safety -22.9%.

What is the intrinsic value of LINCOLN?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Lincoln Pharmaceuticals (LINCOLN) is ₹616.76 (median value). With the current market price of ₹758.15, this represents a -18.6% variance from our estimated fair value.

The valuation range spans from ₹255.49 to ₹878.24, indicating ₹255.49 - ₹878.24.

Is LINCOLN undervalued or overvalued?

Based on our multi-method analysis, Lincoln Pharmaceuticals (LINCOLN) appears to be trading above median value by approximately 18.6%.

LINCOLN Financial Health — Key Ratios vs Industry Benchmarks

Lincoln Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 26.32 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity 11.9% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 16.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.86x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

LINCOLN Cash Flow Quality — Operating & Free Cash Flow

Lincoln Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹93 Cr ₹54 Cr Positive Free Cash Flow 8/10
March 2024 ₹63 Cr ₹35 Cr Positive Free Cash Flow 8/10
March 2023 ₹39 Cr ₹21 Cr Positive Free Cash Flow 8/10
March 2022 ₹76 Cr ₹37 Cr Positive Free Cash Flow 7/10
March 2021 ₹69 Cr ₹37 Cr Positive Free Cash Flow 8/10